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Background: The cell division cycle 20 homolog (CDC20) is an essential cofactor of the anaphase-promoting
complex (APC/C). CDC20 overexpression has been detected in many types of human cancers; however, its clinical
role in colorectal cancer remains unknown.
Methods: Western blotting and immunohistochemistry were used to compare CDC20 expression in adjacent
non-cancerous, cancerous and liver metastatic tissues as well as in colon cancer cell lines and normal colon
epithelial cell lines. Additionally, the correlation of CDC20 expression with patient clinical parameters and its
diagnostic value were statistically analyzed.
Results: CDC20 was overexpressed in colon cancer cell lines/primary cancer tissues compared with normal colon
epithelial cell lines/adjacent noncancerous tissue samples. Interestingly, CDC20 expression was further increased in
metastatic liver tissues. CDC20 protein expression was significantly correlated with clinical stage (P = 0.008),
N classification (P = 0.020), M classification (P = 0.013) and pathologic differentiation (P = 0.008). Patients with
higher CDC20 expression had a shorter overall survival than those with lower CDC20 expression. Univariate and
multivariate analyses indicated that CDC20 expression was an independent prognostic factor (P < 0.001).
Conclusion: CDC20 may serve as a potential prognostic biomarker of human colorectal cancer.
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Colorectal cancer (CRC) is one of the most commonly di-
agnosed cancers and, in recent years, has been the second
leading cause of cancer-related death in China [1]. Surgical
resection remains the primary course of action to cure
CRC in patients with early clinical stages; however, even at
the same stage, the recurrence and survival rates vary
among patients. To date, few genomic markers, such as
microsatellite instability and loss of heterozygosity at
chromosome 18q, are useful for determining the prognosis
of CRC. In this case, improving the molecular markers
available to distinguish an unfavorable prognosis is of great* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orimportance because this group of patients may benefit
from more efficient therapy.
The anaphase-promoting complex/cyclosome (APC/C)
is an E3 ubiquitin ligase that can ubiquitinate certain
substrates for sequential degradation through the ubi-
quitin proteasome pathway [2]. Recent studies have indi-
cated that the APC/C participates in the regulation of
mitosis through ubiquitinating key regulators that have
distinct functions during mitosis including survivin,
securin and cyclins [3,4].
The cell division cycle 20 homolog (CDC20) is a major
cofactor for the APC/C through interaction with specific
elements of its substrates such as the KEN-box, A-box
or D-Box [5,6]. In mammalian cells, CDC20 is required
for APC/C activation at metaphase and participates in
mitotic exit [7]. Recently, the spindle assembly check-
point (SAC) was found to be a monitor of the bipolar
segregation of duplicated chromosomes during the meta-
phase to anaphase transition [2]. SAC dysfunction during. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics and CDC20
expression of 244 patient samples of colorectal cancer





≤ 50 85 (34.8)

























Vital status (at follow-up)
Alive 142 (58.2)
Death (All colorectal cancer-related) 102 (41.8)
Expression of CDC20
Low expression 130 (53.3)
High expression 114 (46.7)
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generation of aneuploid cells, which are considered to be
cancer cells [8]. To date, 7 components of the SAC, which
are MAD1, MAD2, MAD3, BUB1, BUBR1, BUB3 and
CDC20, have been identified. When an error occurs during
sister chromatid segregation, the mitotic checkpoint com-
plex (MCC) is activated, and CDC20 is sequestered by
Mad2 and BubR1/Bub3, which arrests the cell cycle [8]. An
abnormal level or dysfunction of CDC20 may therefore
abolish mitotic arrest and thus promote premature ana-
phase by deregulating APC activation, resulting in aneu-
ploidy in the daughter cells [9]. Interestingly, CDC20 was
recently found to be overexpressed in many types of hu-
man cancers, including human non-small cell lung cancer,
pancreatic cancer, glioma and oral cancer [10-13].
However, the clinical role and function of CDC20
in CRC development remain poorly understood. In
this current study, we investigated CDC20 expression
in CRC and evaluated its prognostic significance by
correlating CDC20 protein expression with the clini-




The human colon epithelial cell line, NCM460, was
obtained from Sun Yat-sen University Cancer Center; two
other human colon epithelial cell lines, CCD841-coN and
CCD112-coN, were purchased from ATCC. Human colon
cancer cell lines DLD1, HT29, HCT116, Lovo, SW620 and
THC8307 were obtained from Sun Yat-sen University
Cancer Center. NCM460, CCD841-coN and CCD112-coN
cells were cultured in MEM medium supplemented with
10% fetal bovine serum (FBS). DLD1, HT29, HCT116,
Lovo and THC8307 cells were cultured in RPMI 1640
medium supplemented with 10% FBS. SW620 cells were
cultured in Leibovitz’s L-15 medium supplemented with
10% FBS. All cells were grown in 10-centimeter cell culture
dishes (NEST Biotechnology, Wuxi, China) in 5% CO2 in a
humidified atmosphere at 37°C.
Tumor specimens
A total of 244 paraffin-embedded archived samples were
used for immunohistochemistry, including 126 samples
with adjacent non-tumorous (ANT) tissues and 20 sam-
ples with liver metastasis. All patients underwent their
initial surgery between 2001 and 2009 at Sun Yat-sen
University Cancer Center after providing informed con-
sent. None of these patients received preoperative ther-
apy. Informed consent from patients and approval from
the Institute Research Ethics Committee were obtained
before the use of the clinical materials. Clinical and
pathologic classification and staging were determined
according to the American Joint Committee on Cancer(AJCC) TNM staging system. Table 1 shows the clinical in-
formation related to the 244 CRC samples. Overall survival
(OS) was defined as the interval between the date of sur-
gery and the date of death or last known follow up.
Western blotting
CDC20 expression was compared between colon cancer
cells and colon normal epithelial cells by Western blotting
Figure 1 Increased expression of CDC20 in colorectal cancer. A, Western blotting analysis of CDC20 expression in normal colon epithelial cell
lines and colon cancer cells. The quantitative data are shown. Bars: SD; *: P < 0.05. B, Immunostaining of CDC20 in six pairs of representative
colorectal tumor tissues (T) with adjacent non-cancerous tissues (N) (left panel). The quantitative analysis is also shown (right panel, Wilcoxon
signed rank test, n = 126, P < 0.001). C, Immunostaining of CDC20 in three pairs of representative primary tumor tissues (P) with liver metastasis
tumor tissues (M) (left panel). The quantitative analysis is also shown (right panel, Wilcoxon signed rank test, n = 20, P < 0.001).
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pression was determined with anti-rabbit immunoglobulin
G (1:2000; Bethyl) according to the manufacturer's sug-
gested protocols. A rabbit anti-α-tubulin monoclonal anti-
body (1:20,000; Abcam) was used as the loading control.
Immunohistochemistry (IHC)
Altered CDC20 protein expression was also studied in 244
human colorectal cancer tissues by immunohistochemis-
try, as described previously [15]. Briefly, the tissue sections
were deparaffinized, rehydrated, endogenous-peroxide-
blocked and antigen-retrieved sequentially and were then
incubated with a rabbit anti-CDC20 antibody (1:150;
Bethyl) overnight at 4°C. Then, the tissue sections were
washed with PBS and treated with anti-rabbit secondary
antibody for 20 minutes, followed by further incubation
with the streptavidin horseradish peroxidase complex.
The sections were developed with diaminobenzidine
tetrahydrochloride (DAB) and further counterstained with
hematoxylin. The degree of immunostaining was evalu-
ated by two independent observers who were blind to the
clinical data of the patients. The percent of positive cells
was scored as ≤ 10% = 0, >10% to ≤ 25% = 1, >25% to ≤




Gender Female 39 (
Male 91 (
Age (years) ≤ 50 43 (
> 50 87 (
Location colon 61 (
rectal 69 (




T classification T1+T2 29 (
T3+T4 101
N classification No 66 (
Yes 64 (
M classification M0 98 (
M1 32 (
Pathologic Differentiation Poor 21 (
Moderate 93 (
Well 16 (
Vital status (as followed up) Alive 91 (
Dead 39 (nuclear staining was scored as negative = 0, weak = 1, mod-
erate = 2, or strong = 3. The two scores were then multi-
plied to calculate the final score. CDC20 expression was
considered low if the final score was equal to or less than
four; otherwise, CDC20 expression was considered high.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package (SPSS Inc., Chicago, IL).
CDC20 expression was compared between tumor tissues
and matched ANT tissues or matched liver metastatic tis-
sues using the Wilcoxon signed rank test. The relationship
between CDC20 expression and clinicopathologic charac-
teristics was analyzed by Pearson’s chi-squared test. Sur-
vival curves were plotted by the Kaplan-Meier method and
compared using the log-rank test. Survival data were evaluated
using univariate andmultivariate Cox regression analyses. A P-
value of less than 0.05was considered statistically significant.
Results
Elevated CDC20 expression in colorectal cancer and
metastatic liver tissues
As shown in Figure 1, CDC20 expression was evaluated
in colorectal cancer cell lines and tissues to investigateopathological characteristics of colorectal cancer patients
20 Chi-square
or none High
cases (%) No. cases (%) test P-value
30.0) 47 (41.2) 0.067
70.0) 67 (58.8)
33.1) 42 (36.8) 0.538
66.9) 72 (63.2)
46.9) 52 (45.6) 0.838
53.1) 62 (54.4)




22.3) 27 (23.7) 0.799
(77.7) 87 (76.3)
50.8) 41 (36.0) 0.020
49.2) 73 (64.0)
75.4) 69 (60.5) 0.013
24.6) 45 (39.5)
16.2) 34 (29.8) 0.008
71.5) 75 (65.8)
12.3) 5 (4.4)
70.0) 51 (44.7) <0.001
30.0) 63 (55.3)
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analysis revealed elevated CDC20 expression in colon
cancer cell lines (DLD1, HT29, HCT116, Lovo, SW620
and THC8307) compared with normal colon epithelial
cell lines (NCM460, CCD841-coN and CCD112-coN)
(Figure 1A, upper row) (Figure 1A, lower row). CDC20
overexpression was further evaluated by IHC in 244
paraffin-embedded colon cancer tissues. As shown in
Figure 1B, CDC20 was primarily localized in the cancer
cell nucleus. Interestingly, a comparison of CDC20 ex-
pression in tumor tissues and ANT tissues in the paired
126 cases showed significant CDC20 overexpression in
cancer cells (Figure 1B, right panel, P < 0.001, Wilcoxon
signed rank test); the representative slides are shown in
Figure 1B, left panel. Moreover, CDC20 expression was
further increased in the matched metastatic liver tissues
compared to the primary cancer tissues, and representa-
tive slides are shown in Figure 1C, left panel. The pri-
mary colorectal cancer tissues were compared to their
respective metastatic liver tissues, and the increase wasFigure 2 Correlation of CDC20 expression and clinicopathologic featu
Representative IHC slides of CDC20 expression in normal colorectal tissues/
strength are shown. B, CDC20 expression in colorectal cancer tissues withsignificant (Figure 1C, right panel, P < 0.001, Wilcoxon
signed rank test). These results together suggested CDC20
overexpression in colorectal cancer.
Correlation between CDC20 expression and
clinicopathologic features of colorectal cancer
We further analyzed the link between CDC20 expression
and the clinical characteristics of colorectal cancer in
244 paraffin-embedded, archival primary colorectal can-
cer tissues by IHC. The samples included 42 cases of
clinical stage I (17.2%), 53 cases of clinical stage II
(21.7%), 72 cases of clinical stage III (29.5%) and 77 cases
of clinical stage IV (31.6%) colorectal cancer. As shown
in Table 1, 114 of the total 244 CRC cases (46.7%) dem-
onstrated high CDC20 expression, whereas 130 cases
(53.3%) had low CDC20 expression.
As shown in Table 2, a statistical analysis revealed a
strong correlation between CDC20 expression and the
clinicopathologic characteristics including clinical stage
(P = 0.008), N classification (P = 0.020), M classificationres. A, Increased expression of CDC20 in advanced colorectal cancer.
colorectal cancer tissues of different clinical stages and the staining
different levels of pathologic differentiation.
Figure 3 Kaplan-Meier curves with univariate analyses (log-rank)
for patients with low CDC20 expression (dotted line) versus high
CDC20 expression (bold line). A-B, The overall survival of patients
(clinical stages I-IV (A) and I-II (B)) with low or high CDC20 expression.
C-D, The overall survival of patients (clinical stages III (C) and IV (D)) with
low or high CDC20 expression.
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vital status (P < 0.001). Representative IHC stained
slides are presented to demonstrate the correlation be-
tween CDC20 expression and clinical stage (Figure 2A)
and pathologic differentiation (Figure 2B), respectively.
Association between CDC20 expression and patient
survival
A Kaplan-Meier analysis and the log-rank test were car-
ried out to evaluate the effects of CDC20 expression and
clinicopathological characteristics on patient survival.
Interestingly, CDC20 expression in colorectal cancer
showed a negative correlation with patient survival time
(P < 0.001). High CDC20 expression indicated a shorter
overall survival (OS) (median OS: 44 months) compared
to lower CDC20 expression (median OS: not reached)
(Figure 3A, P < 0.001). The overall two-, three- and five-
year cumulative survival rates of patients with highTable 3 Univariate and multivariate analyses of various
prognostic parameters in patients with colorectal cancer
using Cox-regression analysis
Variables Univariate analysis Multivariate analysis
No. P value Hazard ratio 95% CI P value
CDC20
Low expression 130 <0.001 2.945 1.944-4.461 <0.001
High expression 114
T classification









M0 167 <0.001 5.733 3.641-9.028 <0.001
M1 77
Differentiation
Poor 55 0.078 0.673 0.476-0.953 0.026
Moderate 168
Well 21
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spectively. For patients with low CDC20 expression,
the rates were 81.5%, 72.3% and 53.8%, respectively
(Figure 3A). Furthermore, CDC20 expression was sig-
nificantly correlated with OS in the advanced clinical
stages (stage III and IV) (Figure 3C-3D, P = 0.026 (C);
P < 0.001(D)). However, no significant correlation between
OS and CDC20 expression was found in the early clinical
stages (stages I and II) (Figure 3B, P = 0.826). Moreover,
multivariate analysis indicated that N classification,
M classification, pathologic differentiation and CDC20 ex-
pression were independent prognostic factors for colorectal
cancer (Table 3).
Discussion
More than one million new cases of CRC occur each year
worldwide, and it has been the second leading disease-
specific cause of mortality in China in recent years [1].
Genomic instability is considered a key hallmark of CRC.
Briefly, there are three subtypes of genomic instability for
CRC, including microsatellite instability (MSI), chromo-
somal instability (CIN) and CpG island methylation pheno-
type (CIMP) [16,17]. Studies have revealed that CIN
occurs in 80%–85% of CRC and that it is the most com-
mon subtype [18]. Later studies discovered that mutations
in genes that regulate the mitotic spindle checkpoint were
responsible for CIN [19]. The SAC is crucial for high-
fidelity mitotic chromosome segregation to maintain gen-
ome integrity. When an error is detected during sister
chromatid segregation, the mitotic metaphase-to-anaphase
checkpoint will be activated, inducing cell arrest. CDC20, a
crucial activator of the anaphase-promoting complex/
cyclosome (APC/C), is then inhibited by Mad2 and
BubR1/Bub3, which prevents premature anaphase. Despite
the altered CDC20 expression found in different types of
cancer [10-13], the tumorigenic role of CDC20 in CRC re-
mains unclear.
In the current study, we demonstrated for the first time
that CDC20 was overexpressed in colon cancer cells com-
pared with normal colon epithelial cells (Figure 1A). Al-
though there was relatively high CDC20 expression in
normal colon epithelial CCD841-coN cells, most likely due
to individual differences, the IHC analysis confirmed the
elevated expression of CDC20 protein in the 126 CRC tis-
sues compared with matched, adjacent non-tumor tissues
(Figure 1B, P < 0.001, Wilcoxon signed rank test, n =126).
Interestingly, CDC20 expression was further increased in
metastatic liver tissues (Figure 1C, P < 0.001, Wilcoxon
signed rank test, n = 20). Higher CDC20 expression signifi-
cantly correlated with advanced tumor stage, poor patho-
logic differentiation and unfavorable prognosis in locally
advanced and advanced clinical stages (Figure 3 and
Table 2). Moreover, the multivariate analysis suggested that
CDC20 was a potential independent prognostic factor forsurvival in CRC patients (Table 3, P < 0.001). However, no
significant correlation was observed between CDC20 ex-
pression and overall survival in stage I~II CRC, most likely
due to the good prognosis in the early stages of CRC and
the limited number of cases.
Recent studies have suggested that CDC20 might be a
potential target for cancer therapy. Cancer cells that do
not undergo apoptosis after mitotic arrest are resistant
to anti-mitotic drugs [20,21]. Premature exit from mi-
totic arrest is considered a mechanism for escaping
apoptosis [22]. Hsiao-Chun Huang et al. demonstrated
that blocking mitotic exit downstream by CDC20 knock-
down was a better strategy for killing apoptosis-resistant,
slippage-prone or SAC-defective cancer cells [23]. Another
study also found that treatment of cancer cells with siRNA
against CDC20 successfully induced G2/M arrest and
suppressed cell growth [24]. In our present study, we found
that clinical stage IV CRC and higher CDC20 expression
were significantly associated with shorter survival time
(Figure 3D, P < 0.001), implying a potential poor response
to oxaliplatin- or irinotecan-based chemotherapy.
To date, the mechanisms involved in the regulation of
CDC20 are poorly understood. One potential mechanism
is transcriptional downregulation of CDC20 by tumor sup-
pressor gene p53 [24]. Moreover, a recent study found that
CDC20 could be deacetylated by SIRT2, a member of the
sirtuins family [25]. Further studies are required to investi-
gate how CDC20 is regulated in cancer cells.Conclusions
In the present study, we found that CDC20 was over-
expressed in CRC and was important for CRC tumorigen-
esis. CDC20 expression was highly associated with clinical
stage, N classification, M classification and pathologic dif-
ferentiation. Patients with higher CDC20 expression had a
shorter predicted overall survival time, and CDC20 was an
independent prognostic factor. These findings may have
broad implications in the clinical treatment of CRC.
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